IDC G103
Alternative Names: G103; Herpes symplex virus 2 vaccine - Immune Design; HSV therapeutic vaccine - Immune Design; HSV2 vaccine + GLA - Immune Design; IDC-G103Latest Information Update: 04 Apr 2022
Price :
$50 *
At a glance
- Originator Immune Design
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Herpes simplex virus type 2 infections
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections in USA
- 17 Aug 2016 IDC G103 is still in preclinical development for Herpes simplex virus type-2 infections in USA (Immune Design pipeline, August 2016; Immune Design 10-Q, April 2016)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections in USA